WO2000067730A1 - Drug delivery device - Google Patents
Drug delivery device Download PDFInfo
- Publication number
- WO2000067730A1 WO2000067730A1 PCT/US2000/012194 US0012194W WO0067730A1 WO 2000067730 A1 WO2000067730 A1 WO 2000067730A1 US 0012194 W US0012194 W US 0012194W WO 0067730 A1 WO0067730 A1 WO 0067730A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- delivery device
- layer
- drag
- drug delivery
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
Definitions
- This invention relates to a drug delivery device for the topical delivery of a hydrophilic drug or drug-containing composition.
- a transdermal drug delivery device also variously referred to as a medical bandage, treatment pad, drug patch, etc.
- a transdermal drug delivery device also variously referred to as a medical bandage, treatment pad, drug patch, etc.
- a drug delivery will include a drug depot, or reservoir, in the form of a drug- storing matrix or carrier and an adhesive for attaching or securing the device to a surface of unbroken skin.
- a drug delivery device which comprises: a) a moisture vapor permeable, liquid impermeable flexible thermoplastic backing layer possessing upper and lower surfaces; b) a moisture vapor permeable, flexible, oleophilic thermoplastic foam layer possessing upper and lower surfaces, the upper surface of the foam layer being nonadhesively bonded to, and substantially coextensive with, the lower surface of the backing layer; c) a pressure sensitive adhesive layer applied to, and substantially coextensive with, the lower surface of the foam layer; and, d) a drug reservoir containing a medicinally effective amount of at least one hydrophilic drug composition and possessing a moisture vapor permeable, but hydrophilic drug composition impermeable, barrier layer applied to one surface thereof, the drug reservoir being applied to a portion of the adhesive layer such that the barrier layer lies between the hydrophilic drug composition and the adhesive layer and prevents any significant migration of such drug composition from the drug reservoir into the adhesive layer.
- the foregoing drug delivery device effectively resists delamination when pulled from the skin and since its hydrophilic drug component remains separated from the adhesive component by a hydrophilic drug composition barrier layer when the drag is contained in the drug reservoir, there is little, if any, likelihood of the hydrophilic drug composition migrating into the adhesive layer and impairing its effectiveness.
- FIG. la is a schematic top cut-away view of a drug delivery device possessing a release liner in accordance with the present invention
- FIG. lb is a cross-sectional view of the drug delivery device of FIG. la;
- FIG. 2a is a schematic top cut-away view of a drug delivery device . containing a protective cover instead of a release liner in accordance with the present invention.
- FIG. 2b is a cross-sectional view of the drug delivery device of FIG. 2a.
- the drug delivery device includes a substantially moisture vapor permeable, liquid impermeable, flexible thermoplastic backing layer 11 possessing upper and lower surfaces with lower surface 18 of backing layer 11 being nonadhesively bonded to, and substantially coextensive with, upper surface 12 of moisture vapor permeable, flexible, oleophilic thermoplastic resin foam layer 13 as generally depicted in FIG. lb.
- Pressure sensitive adhesive layer 14 is applied to, and substantially coextensive with, lower surface 16 of foam layer 13 for securing the drug delivery device to the skin.
- Drug reservoir 24 contains at least one hydrophilic drug composition and possesses a moisture vapor permeable, but hydrophilic drug composition impermeable, barrier layer 15 applied to one surface of reservoir 24.
- Hydrophilic drug composition barrier layer 15 is applied to at least a portion of adhesive layer 14 and separates the hydrophilic drug composition from pressure sensitive adhesive 14 thereby preventing or inhibiting any significant migration of the hydrophilic drug composition into adhesive layer 14 when the drug composition is contained in drug reservoir 24.
- Release liners 17a and 17b seal and protect the adhesive layer 14 and drug reservoir 24 during the residency of drug delivery device 10 within its package with release liner 17a overlapping release liner 17b.
- the ⁇ iinimum strength of the bond between backing layer 11 and foam layer 13 must be sufficient to prevent or inhibit separation, i.e., delamination, of the backing layer from the foam layer under the sort of flexing and/or stretching forces that may be encountered during the useful life of the applied device.
- bond strengths of at least about 2 newtons (N), preferably at least about 3 N and more preferably at least about 5 N will generally provide satisfactory results in this regard.
- MVTR moisture vapor transmission rate
- the MVTR of the backing layer-foam layer subassembly will be at least about 500, preferably at least about 1000 and more preferably at least about 1200, g/m 2 /24 h at 100% r.h. and 32°C as measured by ASTM F1249-90.
- the contact adhesive must impart a peel strength to the drug delivery device, i.e. , the amount of force required to peel the spent drag delivery device from the skin, which is less, preferably at least about 20 percent less and more preferably at least about 40 percent less, than such bond strength in order to prevent or minimize the separation of the backing layer from the foam layer when the spent drug delivery device is peeled from the skin.
- Backing layer 11 can be any thermoplastic film possessing an MVTR of one of the aforestated values.
- the backing layer can be a polyurethane film possessing an average thickness of from about 0.5 to about 3.5 mils and preferably from about 1.0 to about 1.5 mils and a tensile strength of at least about 2500 psi and preferably at least about 3500 psi.
- Foam layer 13 in its as-manufactured state is a moisture vapor permeable, flexible, oleophilic foam that imparts flexural strength to the device since backing layer 11 is in the form of a relatively thin film thereby preventing, for example, curl-up of backing layei 11 when the device is removed from the package and/or release liners 17a and 17b are removed from adhesive layer 14.
- Useful foams generally possess a density of from about 0.8 to about 8.0 and preferably from about 1.2 to about 4.8 lb/ft, a number of pores per inch of from about 30 to about 120 and preferably from about 60 to about 90, and can be fully or partially reticulated or nonreticulated.
- the average thickness of the foam layer can vary from about 20 to about 100 mils and for many applications is preferably from about 30 to about 60 mils.
- Suitable foams that can be employed herein include the untreated oleophilic (i.e, hydrophobic) open cell polyurethane foams disclosed in U.S. Patent No. 5,352,711, the contents of which are incorporated by reference herein. It is particularly advantageous to employ an oleophilic polyurethane foam over a hydrophilic polyurethane foam because when bonding a hydrophilic foam to the backing layer by way of, e,g.
- lower surface 18 of backing layer 11 is bonded to upper surface 12 of foam layer 13 employing a suitable bonding technique, preferably, a flame lamination procedure for the reason stated above.
- Flame lamination, or flame bonding involves the superficial softening or melting of upper surface 12 of foam layer 13 and while surface 12 is in this state, the application of lower surface 18 of backing layer 11 thereto.
- Conditions of the flame lamination operation include the temperature of the flame, the proximity of surface 12 of the foam to the flame and the duration of exposure of this surface to the flame.
- a flame temperature of from about 1800 to about 2200 °C, a distance from the flame to the upper surface of the foam of up to about 3 cm and an exposure time of such surface of from about 25 to about 40 milliseconds will usually provide the desired minimum bond strengths or better.
- vacuum lamination a vacuum is applied to the lower surface of the foam layer and a molten thermoplastic layer intended to provide the backing layer is cast upon the upper surface of the foam layer. The vacuum partially draws the cast layer of molten resin into the structure of the foam so that when the resin cools and solidifies, it provides the backing layer securely bonded to the foam layer.
- Pressure sensitive adhesive layer 14 can be selected from any of the known and conventional medical grade adhesives, e.g., those based on polyacrylic, polyvinylether, or polyurethane resins. It is an essential requirement that the amount of adhesive 14 applied to lower surface 16 of foam layer 13 be sufficient to achieve an acceptable level of adhesion of drug delivery device 10 to the skin but, as previously stated, with a resulting peel strength that is sufficiently below the bond strength between the backing and foam layers. The amount of adhesive that will satisfy these criteria can be readily determined by simple and routine testing. Ordinarily, a medical grade polyacrylic adhesive such as Durotak ® (National Starch & Chemical Company, Bridgewater, NJ) or Gelva ® (Monsanto Inc., St.
- Durotak ® National Starch & Chemical Company, Bridgewater, NJ
- Gelva ® Monsanto Inc., St.
- Drug reservoir 24 can be formed from any conventional material known to one skilled in the art. Useful materials include polyurethane foam, woven or nonwoven cellulose or other natural synthetic or nonsynthetic material and the like. Generally, a large variety of hydrophilic drag compositions can be incorporated into drug reservoir 24 of drag delivery device 10 by, e.g., applying the drug in a fluid or semi-fluid state so that the composition spreads out somewhat from its initial application point to reservoir 24. However, after reaching the maximum extent of its spread and hardening, the drag composition will be lying in reservoir 24 and separated from adhesive layer 14 by barrier layer 15.
- hydrophilic drag is used herein in its broadest sense as referring to any drug or drag-containing composition that can be formulated with a polar material, e.g., water, alcohols such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol, etc. and the like.
- a polar material e.g., water, alcohols such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol, etc. and the like.
- the drag or drug-containing composition that can be formulated with the polar material(s) can be any substance or composition possessing therapeutically or medicinally beneficial activity and includes prescription and nonprescription pharmaceuticals, medicinals, medicaments, active ingredients of cosmetic and personal care preparations, and the like.
- hydrophilic drag composition examples include topically delivered local anesthetics such as benz ⁇ caine, procaine hydrochloride, tetracaine, tetracaine hydrochloride, dibucaine, lidocaine, lidocaine hydrochloride, bupivicaine, dyclonin, etidocaine, mepivicaine, butamen picrate, dimethisoquin hydrochloride, cyclomethylcaine sulfate, and the like; analgesics and anti-inflammatory agents such as buprenorphin, butophanol tartrate, acetaminophen, fentanyl, mefenamic acid, flutenamic acid, diclofenac, oxyphenbutazone, phenybutazone, ibuprofen, flurbiprofen, naproxen, menthol, methyl salicylate, phenol, salicylic acid, benzyl alcohol, camphor, camphora
- Vitamin C Vitamin C
- Vitamin E Vitamin E
- Suitable diffusable oleophilic medium e.g., an ointment, paste or other oleophilic vehicle
- suitable diffusable oleophilic medium e.g., an ointment, paste or other oleophilic vehicle
- emulsion formulations for use herein include the following: 1. Vegetable oil 10.0%, Petrolatum 3.0% , Beeswax, 12.0%,
- Cetearyl alcohol 4.0%, Light mineral oil 22.0%, Preservative 0.2%, Antioxidant
- penetration enhancers that can be used herein are butylene glycol, capric acid, caproic acid, caprylic acid, caprylic/capric triglyceride, diethylene glycol, diethylene glycol monoethyl ether, glycerin, glyceryl dioleate, glycerol monooleate, glycerol trioleate, hexylene glycol, isopropylmyristate, isopropylpalmitate, linoleic acid, methyl laurate, oleic acid, oleyl alcohol, polyethylene glycol 200, polyethylene glycol dilaurate, propyl oleate, propylene glycol, squalene, and the like.
- the hydrophilic drag composition used herein can also contain at least one other pharmacologically active or non-active substance, e.g., narcotic analgesics such as codeine, oxycodeine, dihydrocodeine, hydrocodone, levorphanol, morphine, and the like.
- narcotic analgesics such as codeine, oxycodeine, dihydrocodeine, hydrocodone, levorphanol, morphine, and the like.
- barrier layer 15 can be applied to one side of reservoir 24 either prior to, during or following barrier layer 15 being applied to adhesive layer 14 employing any suitable technique known to one skilled in the art, e.g., by way of an adhesive, or by coating a molten material on one side of drug reservoir 24 or adhesive layer 14 or by coating a solution containing a solvent on one side of reservoir 24 or adhesive layer 14 wherein the solvent will substantially evaporate thereby forming a thin film, i.e., barrier layer 15.
- barrier layer 15 separates drag reservoir 24 from adhesive layer 14.
- the barrier layer 15 therefore prevents or inhibits any significant migration of the hydrophilic drug composition from drug reservoir 24 into adhesive layer 14 once the drug composition has been incorporated into reservoir 24 where it could destroy or impair the effectiveness of adhesive layer 14 in securing the drug delivery device to the skin.
- Another advantageous characteristic of the drag delivery device herein is its ability to maintain continuous contact between the hydrophilic drug composition and the skin thus assuring that the drug will be constantly available at the site of its administration.
- Useful materials for forming hydrophilic drag composition barrier layer 15 include, for example, perforated polyethylene, perforated polyurethane and the like.
- the thickness of the barrier layer 15 can vary from less than about 2.0 mils and preferably less than about 1.0 mils.
- Drag delivery device 10 can be manufactured in a variety of sizes and shapes and can be planar or three-dimensional.
- the drug delivery device can also possess a protective cover 30 instead of release liners 17a and 17b as shown generally in FIG. 2a at 20.
- a protective cover 30 instead of release liners 17a and 17b as shown generally in FIG. 2a at 20.
- Covers of this kind are known from U.S. Patent No. 4,627,429, the contents of which are incorporated by reference herein.
- protective cover 30 can be made, for example, of a heat- sealable aluminum foil film laminate with heat-sealable surface down.
- a formed cup, dome or square in cover 30 allows room for reservoir 24 with the other portion of cover 30 being placed over the adhesive layer 14 as generally depicted in FIG. 2b.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU49856/00A AU4985600A (en) | 1999-05-07 | 2000-05-04 | Drug delivery device |
CA002369328A CA2369328A1 (en) | 1999-05-07 | 2000-05-04 | Drug delivery device |
JP2000616757A JP2002544157A (en) | 1999-05-07 | 2000-05-04 | Drug release device |
EP00932074A EP1176951A1 (en) | 1999-05-07 | 2000-05-04 | Drug delivery device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/307,051 US6277401B1 (en) | 1999-05-07 | 1999-05-07 | Drug delivery device |
US09/307,051 | 1999-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000067730A1 true WO2000067730A1 (en) | 2000-11-16 |
Family
ID=23188026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/012194 WO2000067730A1 (en) | 1999-05-07 | 2000-05-04 | Drug delivery device |
Country Status (6)
Country | Link |
---|---|
US (1) | US6277401B1 (en) |
EP (1) | EP1176951A1 (en) |
JP (1) | JP2002544157A (en) |
AU (1) | AU4985600A (en) |
CA (1) | CA2369328A1 (en) |
WO (1) | WO2000067730A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10128685A1 (en) * | 2001-06-13 | 2002-12-19 | Beiersdorf Ag | Self-adhesive sticking plaster matrix material comprising active material and penetration enhancer, useful for skin care, especially controlled application of active material to skin |
DE10220114A1 (en) * | 2002-05-06 | 2003-11-20 | Beiersdorf Ag | Drug delivery system used for controlled release of essential oils comprises matrix plaster based on self adhesive, gas permeable polyurethane |
FR2905601A1 (en) * | 2006-09-11 | 2008-03-14 | Innoderm Sarl | Use of oleic derivatives as a method and composition promoting dermal penetration of active agents present in cosmetic, pharmaceutical or dermatological compositions |
WO2009085302A2 (en) | 2007-12-28 | 2009-07-09 | Newmedical Technology, Inc. | Method and multilayered device for controlled topical delivery of therapeutic agents to the skin |
US7943166B2 (en) | 2003-04-10 | 2011-05-17 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
US8591940B2 (en) | 2004-01-02 | 2013-11-26 | New Medical Technology Inc. | Method of treating scar tissue |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6617014B1 (en) * | 1999-09-01 | 2003-09-09 | Hydrophilix, Llc | Foam composite |
DE19954421A1 (en) | 1999-11-12 | 2001-05-31 | Lohmann Therapie Syst Lts | Film-like preparation for the biphase release of pharmacologically active or other substances |
FR2830766B1 (en) * | 2001-10-12 | 2004-03-12 | Optis France Sa | DEVICE OF ISSUE OF DRUGS THROUGH IONTOPHORESIS TRANSPALPEBRALE |
US8790688B2 (en) * | 2001-12-21 | 2014-07-29 | Coloplast A/S | Wound care device for local treatment of pain in a wound |
US6916463B2 (en) * | 2002-09-24 | 2005-07-12 | The Procter & Gamble Company | Oral products having an aesthetic layer |
MXPA05010882A (en) * | 2003-04-08 | 2005-11-25 | Algorx Pharmaceuticals Inc | Preparation and purification of synthetic capsaicin. |
EP1514539A3 (en) * | 2003-05-14 | 2005-05-04 | Signal Investment & Management Co. | Micro-encapsulated topical analgesic for pain relief and sleeve comprising it |
US8524272B2 (en) * | 2003-08-15 | 2013-09-03 | Mylan Technologies, Inc. | Transdermal patch incorporating active agent migration barrier layer |
FR2870741B1 (en) * | 2004-05-25 | 2008-03-14 | Coletica Sa | HYDRATED LAMELLAR OR LIPOSOME PHASE CONTAINING A FATTY MONOAMINE OR A CATIONIC POLYMER PROMOTING INTERCELLULAR PENETRATION AND A COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING THE SAME. |
US7704522B2 (en) * | 2004-09-08 | 2010-04-27 | Clyde Morgan | Topical medicament |
CN101119713A (en) * | 2004-11-24 | 2008-02-06 | 阿尔高克斯制药公司 | Capsaicinoid gel formulation and uses thereof |
US7955677B2 (en) * | 2005-12-07 | 2011-06-07 | Mylan Technologies, Inc. | Two-sided non-stick release film |
CN101528830A (en) | 2006-07-10 | 2009-09-09 | 麦德医像公司 | Super elastic epoxy hydrogel |
CA2600249C (en) * | 2006-09-12 | 2014-05-20 | Tyco Healthcare Group Lp | Thin film dressing |
WO2009073734A2 (en) | 2007-12-03 | 2009-06-11 | Medipacs, Inc. | Fluid metering device |
US8329210B2 (en) * | 2008-09-23 | 2012-12-11 | Pharmapatch, Llc | Twin transdermal drug delivery patch |
WO2011032011A1 (en) | 2009-09-10 | 2011-03-17 | Medipacs, Inc. | Low profile actuator and improved method of caregiver controlled administration of therapeutics |
US9500186B2 (en) | 2010-02-01 | 2016-11-22 | Medipacs, Inc. | High surface area polymer actuator with gas mitigating components |
DK2552245T3 (en) | 2010-03-26 | 2019-01-07 | Philip Morris Products Sa | INHIBITION OF SENSORY IRRITATION UNDER CONSUMPTION OF NON-SMOKABLE TOBACCO PRODUCTS |
US8952038B2 (en) | 2010-03-26 | 2015-02-10 | Philip Morris Usa Inc. | Inhibition of undesired sensory effects by the compound camphor |
WO2012061556A1 (en) | 2010-11-03 | 2012-05-10 | Flugen, Inc. | Wearable drug delivery device having spring drive and sliding actuation mechanism |
EP2710085B1 (en) * | 2011-05-16 | 2018-09-26 | Avery Dennison Corporation | Adhesive containing microparticles |
CA2906274A1 (en) | 2012-03-14 | 2013-09-19 | Medipacs, Inc. | Smart polymer materials with excess reactive molecules |
CN110063836A (en) * | 2014-04-23 | 2019-07-30 | 塞罗斯医学有限责任公司 | Vacuum aided drug delivery device |
US20170042311A1 (en) | 2014-10-21 | 2017-02-16 | The Procter & Gamble Company | Method of Improving Skin Appearance |
US20160287447A1 (en) * | 2015-04-01 | 2016-10-06 | Timothy MOORADD | Medicated pad for a chinstrap |
WO2017070078A1 (en) * | 2015-10-22 | 2017-04-27 | The Procter & Gamble Company | Barrier patch of a foamed film and methods of improving skin appearance |
WO2017070082A1 (en) * | 2015-10-22 | 2017-04-27 | The Procter & Gamble Company | Barrier patch of a foamed film and methods of improving skin appearance |
US11622929B2 (en) | 2016-03-08 | 2023-04-11 | Living Proof, Inc. | Long lasting cosmetic compositions |
US10857076B2 (en) | 2017-01-09 | 2020-12-08 | The Procter & Gamble Company | Barrier patch with soluble film and methods of improving skin appearance |
WO2018129495A1 (en) | 2017-01-09 | 2018-07-12 | The Procter & Gamble Company | Barrier patch with soluble film and methods of improving skin appearance |
US10751265B2 (en) | 2017-01-09 | 2020-08-25 | The Procter & Gamble | Barrier patch with soluble film and methods of improving skin appearance |
USD830530S1 (en) | 2017-03-17 | 2018-10-09 | Novia Products, Llc | Scent dispenser |
CN110769945B (en) | 2017-06-22 | 2023-01-24 | 宝洁公司 | Cosmetic care film comprising a water-soluble layer and a vapor-deposited coating |
US10842729B2 (en) | 2017-09-13 | 2020-11-24 | Living Proof, Inc. | Color protectant compositions |
JP7244495B2 (en) | 2017-09-13 | 2023-03-22 | リビング プルーフ インコーポレイテッド | Long lasting cosmetic composition |
US10912855B2 (en) | 2017-11-02 | 2021-02-09 | Novia Products, Llc | Scent dispenser/absorber and method using same |
WO2019183010A1 (en) | 2018-03-19 | 2019-09-26 | The Procter & Gamble Company | Method of making a barrier patch with soluble film |
US11207439B2 (en) | 2018-05-01 | 2021-12-28 | Novia Products, Llc | Scent dispenser/absorber |
USD910159S1 (en) | 2019-01-30 | 2021-02-09 | Novia Products, Llc | Scent dispenser |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997006788A1 (en) * | 1995-08-14 | 1997-02-27 | Janssen Pharmaceutica N.V. | Transdermal administration of vorozole |
WO1998053825A1 (en) * | 1997-05-27 | 1998-12-03 | Algos Pharmaceutical Corporation | Analgesic drug composition containing a capsaicinoid and potentiator therefor |
US5891463A (en) * | 1996-07-03 | 1999-04-06 | U.S. Dermatologics, Inc. | Nonocclusive drug delivery device and process for its manufacture |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4710191A (en) | 1985-12-16 | 1987-12-01 | Jonergin, Inc. | Therapeutic device for the administration of medicaments |
US4627429A (en) | 1986-02-28 | 1986-12-09 | American Home Products Corporation | Storage-stable transdermal adhesive patch |
US5820876A (en) | 1986-08-28 | 1998-10-13 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system |
AU607172B2 (en) * | 1986-12-22 | 1991-02-28 | Cygnus, Inc. | Diffusion matrix for transdermal drug administration |
US5593395A (en) * | 1987-08-07 | 1997-01-14 | Martz; Joel D. | Vapor permeable dressing |
US5061258A (en) * | 1987-08-07 | 1991-10-29 | Martz Joel D | Vapor permeable dressing with releasable medication |
US4839174A (en) | 1987-10-05 | 1989-06-13 | Pharmetrix Corporation | Novel transdermal nicotine patch |
US4983395A (en) | 1987-11-12 | 1991-01-08 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US4849224A (en) * | 1987-11-12 | 1989-07-18 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
JP2670680B2 (en) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | Polylactic acid microspheres containing physiologically active substance and method for producing the same |
US5008110A (en) * | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
US5264218A (en) | 1989-10-25 | 1993-11-23 | C. R. Bard, Inc. | Modifiable, semi-permeable, wound dressing |
US5352711A (en) | 1991-08-12 | 1994-10-04 | The Proctor & Gamble Company | Method for hydrophilizing absorbent foam materials |
JPH0679002A (en) | 1993-12-14 | 1994-03-22 | Hisamitsu Pharmaceut Co Inc | Patch device for percutaneous administration |
US5503844A (en) | 1993-05-18 | 1996-04-02 | Mli Acquisition Corp. Ii | Foam laminate transdermal patch |
DE4341444C2 (en) | 1993-12-04 | 1996-03-14 | Lohmann Therapie Syst Lts | Active substance-containing plaster and process for its production |
US5536263A (en) | 1994-03-30 | 1996-07-16 | Lectec Corporation | Non-occulusive adhesive patch for applying medication to the skin |
US5891461A (en) * | 1995-09-14 | 1999-04-06 | Cygnus, Inc. | Transdermal administration of olanzapine |
US5807570A (en) * | 1995-09-29 | 1998-09-15 | Cygnus, Inc. | Transdermal administration of ropinirole and analogs thereof |
-
1999
- 1999-05-07 US US09/307,051 patent/US6277401B1/en not_active Expired - Fee Related
-
2000
- 2000-05-04 EP EP00932074A patent/EP1176951A1/en not_active Withdrawn
- 2000-05-04 CA CA002369328A patent/CA2369328A1/en not_active Abandoned
- 2000-05-04 WO PCT/US2000/012194 patent/WO2000067730A1/en not_active Application Discontinuation
- 2000-05-04 JP JP2000616757A patent/JP2002544157A/en active Pending
- 2000-05-04 AU AU49856/00A patent/AU4985600A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997006788A1 (en) * | 1995-08-14 | 1997-02-27 | Janssen Pharmaceutica N.V. | Transdermal administration of vorozole |
US5891463A (en) * | 1996-07-03 | 1999-04-06 | U.S. Dermatologics, Inc. | Nonocclusive drug delivery device and process for its manufacture |
WO1998053825A1 (en) * | 1997-05-27 | 1998-12-03 | Algos Pharmaceutical Corporation | Analgesic drug composition containing a capsaicinoid and potentiator therefor |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10128685A1 (en) * | 2001-06-13 | 2002-12-19 | Beiersdorf Ag | Self-adhesive sticking plaster matrix material comprising active material and penetration enhancer, useful for skin care, especially controlled application of active material to skin |
DE10220114A1 (en) * | 2002-05-06 | 2003-11-20 | Beiersdorf Ag | Drug delivery system used for controlled release of essential oils comprises matrix plaster based on self adhesive, gas permeable polyurethane |
US10653647B2 (en) | 2003-04-10 | 2020-05-19 | Grt Us Holding, Inc. | Methods and compositions for administration of TRPV1 agonists |
US9750707B2 (en) | 2003-04-10 | 2017-09-05 | Acorda Therapeutics, Inc. | Methods and compositions for administration of TRPV1 agonists |
US8734770B2 (en) | 2003-04-10 | 2014-05-27 | Acorda Therapeutics, Inc. | Methods and compositions for administration of TRPV1 agonists |
US7943166B2 (en) | 2003-04-10 | 2011-05-17 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
US8263093B2 (en) | 2003-04-10 | 2012-09-11 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
US8273390B2 (en) | 2003-04-10 | 2012-09-25 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
US8591940B2 (en) | 2004-01-02 | 2013-11-26 | New Medical Technology Inc. | Method of treating scar tissue |
FR2905601A1 (en) * | 2006-09-11 | 2008-03-14 | Innoderm Sarl | Use of oleic derivatives as a method and composition promoting dermal penetration of active agents present in cosmetic, pharmaceutical or dermatological compositions |
EP2237772A4 (en) * | 2007-12-28 | 2013-01-30 | Newmedical Technologies Inc | Method and multilayered device for controlled topical delivery of therapeutic agents to the skin |
EP2237772A2 (en) * | 2007-12-28 | 2010-10-13 | Newmedical Technologies, Inc. | Method and multilayered device for controlled topical delivery of therapeutic agents to the skin |
WO2009085302A2 (en) | 2007-12-28 | 2009-07-09 | Newmedical Technology, Inc. | Method and multilayered device for controlled topical delivery of therapeutic agents to the skin |
Also Published As
Publication number | Publication date |
---|---|
US6277401B1 (en) | 2001-08-21 |
AU4985600A (en) | 2000-11-21 |
CA2369328A1 (en) | 2000-11-16 |
JP2002544157A (en) | 2002-12-24 |
EP1176951A1 (en) | 2002-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6277401B1 (en) | Drug delivery device | |
US5891463A (en) | Nonocclusive drug delivery device and process for its manufacture | |
US5505958A (en) | Transdermal drug delivery device and method for its manufacture | |
US7063859B1 (en) | Barrier film lined backing layer composition and method for topical administration of active agents | |
JP6576039B2 (en) | Adhesive patch assembly having an overlay liner and systems and methods for making the same | |
US3731683A (en) | Bandage for the controlled metering of topical drugs to the skin | |
US4573996A (en) | Device for the administration of an active agent to the skin or mucosa | |
JP5501782B2 (en) | Transdermal delivery system capable of titration | |
EP0674913B1 (en) | Non-occulusive adhesive patch for applying medication to the skin | |
JPH0679002A (en) | Patch device for percutaneous administration | |
US20100292660A1 (en) | Dermal delivery device with ultrasonic weld | |
SK278995B6 (en) | Method for producing transdermal therapeutic plaster | |
WO2015133329A1 (en) | Patch preparation | |
EP1352649B1 (en) | Patch and production method thereof | |
US5972376A (en) | Transdermal system of tacrine/selegilin-plaster | |
AU584025B2 (en) | Bandage for sustained delivery of drugs | |
JP4317075B2 (en) | Patch | |
JPS6059208B2 (en) | complex preparation | |
KR20010073008A (en) | Plaster containing a medicament, with three functional layers | |
CS261105B1 (en) | Transdermal therapeutic system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2369328 Country of ref document: CA Ref country code: CA Ref document number: 2369328 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000932074 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 616757 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000932074 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000932074 Country of ref document: EP |